US EditionCogent Biosciences Reports Encouraging Results for BEZUCLASTINIB in Indolent Systemic Mastocytosis – Patient Worthy
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Cogent Biosciences Reports Encouraging Results for BEZUCLASTINIB in Indolent Systemic Mastocytosis – Patient Worthy
Cogent Biosciences has announced new clinical trial results indicating that its drug BEZUCLASTINIB offers promising benefits for patients with indolent systemic mastocytosis (ISM), a rare and chronic disorder characterized by the accumulation of mast cells in various organs. This disease can cause a wide range of debilitating symptoms, including skin lesions, gastrointestinal issues, and severe […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium